| PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis F Passiglia, G Bronte, V Bazan, C Natoli, S Rizzo, A Galvano, A Listì, ... Oncotarget 7 (15), 19738, 2016 | 175 | 2016 |
| Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective … A Russo, M Russano, T Franchina, MR Migliorino, G Aprile, G Mansueto, ... Advances in Therapy 37 (3), 1145-1155, 2020 | 160 | 2020 |
| Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway D Massihnia, A Galvano, D Fanale, A Perez, M Castiglia, L Incorvaia, ... Oncotarget 7 (37), 60712, 2016 | 133 | 2016 |
| Programmed death ligand 1 (PD-L1) as a predictive biomarker for pembrolizumab therapy in patients with advanced non-small-cell lung cancer (NSCLC) L Incorvaia, D Fanale, G Badalamenti, N Barraco, M Bono, LR Corsini, ... Advances in therapy, 1-18, 2019 | 123 | 2019 |
| The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal V Gristina, U Malapelle, A Galvano, P Pisapia, F Pepe, C Rolfo, S Tortorici, ... Cancer Treatment Reviews, 101994, 2020 | 119 | 2020 |
| Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis F Passiglia, G Bronte, V Bazan, A Galvano, B Vincenzi, A Russo Critical reviews in oncology/hematology 99, 150-157, 2016 | 106 | 2016 |
| Erratum to: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis (Scientific Reports,(2018 … F Passiglia, S Rizzo, M Di Maio, A Galvano, G Badalamenti, A Listì, ... | 100* | 2018 |
| Looking for the best immune‐checkpoint inhibitor in pre‐treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab F Passiglia, A Galvano, S Rizzo, L Incorvaia, A Listi, V Bazan, A Russo International journal of cancer 142 (6), 1277-1284, 2018 | 97 | 2018 |
| New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS? G Bronte, N Silvestris, M Castiglia, A Galvano, F Passiglia, G Sortino, ... Oncotarget 6 (28), 24780, 2015 | 97 | 2015 |
| The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis F Passiglia, S Rizzo, M Di Maio, A Galvano, G Badalamenti, A Listì, ... Scientific reports 8 (1), 1-10, 2018 | 95 | 2018 |
| Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial S De Placido, C Gallo, M De Laurentiis, G Bisagni, G Arpino, MG Sarobba, ... The Lancet Oncology 19 (4), 474-485, 2018 | 95 | 2018 |
| Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients F Passiglia, A Galvano, M Castiglia, L Incorvaia, V Calò, A Listì, ... Therapeutic Advances in Medical Oncology 11, 1758835919839928, 2019 | 62 | 2019 |
| Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis A Mancuso, A Mazzola, G Cabibbo, G Perricone, M Enea, A Galvano, ... Digestive and Liver Disease 47 (4), 324-330, 2015 | 57 | 2015 |
| The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? G Bronte, L Incorvaia, S Rizzo, F Passiglia, A Galvano, F Rizzo, C Rolfo, ... Critical reviews in oncology/hematology 107, 20-32, 2016 | 50 | 2016 |
| Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score A Galvano, M Peri, AA Guarini, M Castiglia, A Grassadonia, M De Tursi, ... Therapeutic Advances in Medical Oncology 12, 1758835920942378, 2020 | 48 | 2020 |
| Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials A Battaggia, A Donzelli, M Font, D Molteni, A Galvano PloS one 10 (4), e0124587, 2015 | 46 | 2015 |
| COVID-19 infection in cancer patients: how can oncologists deal with these patients? O Brunetti, A Derakhshani, B Baradaran, A Galvano, A Russo, N Silvestris Frontiers in Oncology 10, 734, 2020 | 45 | 2020 |
| Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus D Cabibi, S Caruso, V Bazan, M Castiglia, G Bronte, S Ingrao, D Fanale, ... Oncotarget 7 (30), 47821, 2016 | 41 | 2016 |
| Metastatic site location influences the diagnostic accuracy of ctDNA EGFR-mutation testing in NSCLC patients: a pooled analysis F Passiglia, S Rizzo, C Rolfo, A Galvano, E Bronte, L Incorvaia, A Listi, ... Current cancer drug targets 18 (7), 697-705, 2018 | 40 | 2018 |
| The use of SAMe in chemotherapy-induced liver injury B Vincenzi, A Russo, A Terenzio, A Galvano, D Santini, F Vorini, ... Critical reviews in oncology/hematology 130, 70-77, 2018 | 39 | 2018 |
